[Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds]. 1995

M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
Centre SIDA de l'Université McGill, Institut Lady Davis-Hôpital général juif, Montréal, Québec, Canada.

The prolonged use of anti-viral nucleosides (ZDV, ddI, ddC) in HIV-infected patients has given rise to the isolation of viral variants that display resistance against these compounds. Tissue culture selection experiments, involving increasing concentrations of anti-viral compounds, have likewise been shown to select for drug-resistant strains of HIV. Cloning, sequencing and site-directed mutagenesis have shown that a series of point mutations in the viral reverse transcriptase (RT) are responsible for this phenomenon. A different series of mutations in RT are responsible for resistance against non-nucleoside inhibitors of this enzyme. These mutations are due to the error-prone nature of RT during viral replication. Mutated forms of recombinant RT, that derive from drug-resistant viruses, have reduced affinity for relevant triphosphorylated nucleosides.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug

Related Publications

M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
January 1992, BJR supplement,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
September 2000, Cellular and molecular life sciences : CMLS,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
August 1975, Annals of the New York Academy of Sciences,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
November 2010, Viruses,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
April 1998, Biochemistry,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
August 2004, Current drug metabolism,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
May 2006, Mini reviews in medicinal chemistry,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
January 2011, Molekuliarnaia biologiia,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
October 2001, HIV medicine,
M A Wainberg, and Z Gu, and H Salomon, and E J Arts, and L Kleiman, and M A Parniak, and N Morin
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Copied contents to your clipboard!